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Edited by Michael R. BubbAbstract An immunoproteasome subunit low molecular weight
protein 7 (LMP7) plays critical roles in major histocompatibility
complex class I antigen processing; however, the mechanism for
its expression has remained unclear. We demonstrate that inter-
feron (IFN) regulatory factor-1 (IRF-1) has a pivotal role in
IFN-c-dependent LMP7 expression, as was shown for the other
two immunosubunits. A tetracycline-inducible system for IRF-1
revealed its function in the LMP7 expression, and a genomic re-
gion functionally interacting with IRF-1 was also determined.
Furthermore, the role of IRF-1 in IFN-c-inducible LMP7 tran-
scription was conﬁrmed by employing small interfering RNA
experiments and IRF-1/ mice. These results suggest that
IRF-1 acts as a master regulator for the concerted expression
of immunoproteasome components.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The proteasome plays an essential role in the processing of
major histocompatibility complex class (MHC) I ligands [1]
in most somatic cells to mediate immune responses against
viruses and tumor cells [2]. Upon exposure of cells to inter-
feron-c (IFN-c), three catalytic subunits of the proteasome,
low molecular weight protein 7 (LMP7), LMP2, and multicat-
alytic endopeptidase complex-like 1 (MECL1), are expressedAbbreviations: IRF-1, interferon regulatory factor-1; IFN, interferon;
LMP, low molecular weight protein; MECL1, multicatalytic endopep-
tidase complex-like 1; MHC, major histocompatibility complex; TET,
tetracycline; DOX, doxycycline; RT-PCR, reverse transcriptase-poly-
merase chain reaction; G3PDH, glyceraldehyde-3-phosphate dehydro-
genase; MIG, monokine induced by interferon-c; siRNA, small
interfering RNA; ChIP assay, chromatin immunoprecipitation assay;
STAT, signal transducer and activator of transcription; TNF-a, tumor
necrosis factor-a
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its’’ replace the constitutive catalytic subunits, resulting in the
formation of so-called immunoproteasomes, and alter the pro-
tein cleavage speciﬁcity so that more eﬃcient class I antigen
processing could be achieved [6–8,10–12].
There is increasing evidence that LMP7 plays pivotal roles in
antigen presentation. Its eﬀects on the peptidase speciﬁcity of
the proteasome [11] or on eﬃcient processing of several epi-
topes [13–15] were demonstrated by in vitro studies. Its role
in antigen processing was also shown by in vivo experiments
that employed LMP7-deﬁcient mice [16]. In addition, studies
have shown that the coexistence of LMP7 with the other imm-
unosubunits facilitates the antigen presentation irrespective of
its catalytic activity, indicating the importance of LMP7 for
proper assembly of the immunoproteasome [15,17]. Therefore,
investigating the regulatory mechanism for the expression of
LMP7 and its mechanical association with those for the other
two immunosubunits would have impacts on our understand-
ing of the molecular basis for class I antigen processing; how-
ever, this issue has remained totally unclear. It was reported
that IFN-c-dependent expression of both LMP2 [18–20] and
MECL1 [21] is regulated by a transcription factor IFN regula-
tory factor-1 (IRF-1), one among a variety of eﬀector mole-
cules in IFN-c-mediated signaling that evokes a variety of
immune responses [22,23]. Given a biological rationale for
the ﬁnely tuned expression of the immunosubunits in response
to IFN-c and the presence of a common factor for this process,
we were particularly interested in examining the role of IRF-1
in the induction of LMP7 by IFN-c. We here show that IRF-1
serves as a transcriptional activator for LMP7 both in vitro
and in vivo, indicating the central role of IRF-1 in the prere-
quisite step for the class I antigen processing.2. Materials and methods
2.1. Cell culture
HeLa and human colonic epithelial DLD-1 cells were grown in
DMEM supplemented with 10% fetal bovine serum and 1% penicil-
lin–streptomycin. Two sublines of DLD-1, DLD-1/tetracycline
(TET)-repressor (TR) cells and DLD-1/TR/IRF-1-tag cells, were
established and grown as previously described [24]. Cells were seeded
at a density of 3 · 105 cells/ml in the medium 36 h prior to each exper-
iment and, when indicated, were stimulated with either 50 ng/ml of
human IFN-c (PeproTech, London, UK) or 100 ng/ml of doxycycline
(DOX) (Clontech, Palo Alto, CA, USA).blished by Elsevier B.V. All rights reserved.
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Mice deﬁcient in IRF-1 with a background of C57BL/6 [25], a kind
gift of Dr. S. Taki (Shinshu University), and IRF-1+/+ mice derived
from the heterozygous littermates were maintained under speciﬁc path-
ogen-free facility at Tokyo Medical and Dental University. All mice
were genotyped and used at 20 weeks of age. For in vivo studies, mice
were injected i.p. with 1 · 105 U per body of murine IFN-c (Pepro-
Tech) or vehicle alone (n = 2 per group). After 6 h of injection, colon
and liver samples from individual mice were isolated and subjected
to total RNA extraction as described below. The institutional review
board has approved our experimental animal studies.2.3. Total RNA isolation and cDNA synthesis
Total RNA was isolated from the cultured cells or from the murine
tissues by the standard protocol using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturers instructions.
When required, RNA samples were subjected to cDNA synthesis as
previously described [24], yielding a ﬁnal volume of 21 ll from a total
RNA aliquots of 5 lg.Fig. 1. Forced expression of IRF-1 upregulates expression of not only
LMP2 and MECL1 mRNAs, but also LMP7 mRNA which encodes
functional LMP7 protein. (A) Parental DLD-1 (DLD-1) or its sublines
DLD-1/TR and DLD-1/TR/IRF-1-tag (DLD-1/TR/IRF-1) cells were
stimulated with IFN-c (50 ng/ml) or DOX (100 ng/ml), respectively,
for indicated time periods. Total RNA was isolated and 13 lg of each
was subjected to Northern blotting for IRF-1, LMP7, LMP2, MECL1
and G3PDH (loading controls) by using the 32P-labeled cDNA probes.
(B) Schematic diagram of the human LMP7 gene and its transcripts
LMP7-E1 and -E2 (top) [26]. Nucleotide numbers were given with
respect to the 5 0 end of the LMP7-E1 (+1). The positions for the
primers S-LMP7-E1 (S-E1), S-LMP7-E2 (S-E2) and AS-LMP7-E1/E2
(AS-E1/E2) are shown with arrows (top). DLD-1 or DLD-1/TR/IRF-1
cells were stimulated with IFN-c (50 ng/ml) or DOX (100 ng/ml),
respectively, collected before and after 12 h of stimulation for total
RNA isolation, and then a semi-quantitative multiplex RT-PCR for
LMP7 was carried out (bottom). As positive controls, equal amounts
of the plasmids pGEM-LMP7-E1 and -E2 were mixed and the PCR
was performed using 15 or 150 pg (7.5 or 75 pg for each plasmid) of the
mixed plasmid as a template. The right panel shows the expression
levels of the G3PDH gene as controls.2.4. Northern blot and RT-PCR
Northern blotting was carried out essentially as described previously
[24] by using 13 lg of each total RNA sample. The cDNA probes for
the human IRF-1, LMP7, LMP2, MECL1 and glyceraldehyde-3-phos-
phate dehydrogenase (G3PDH) genes were generated by RT-PCR.
Primers were as follows: sense (S)-IRF-1, 5 0-TTCCCTCTTCCACTCG
GAGT-3 0 and antisense (AS)-IRF-1, 5 0-GATATCTGGCAGGGAGT
TCA-3 0 for IRF-1; S-LMP7-E2 (see below), 5 0-ATGGCGCTACTA-
GATGTATGCGGA-3 0 and AS-LMP7-E1/E2 (see below), 5 0-TTGAT
TGGCTTCCCGGTACTGGTGC-3 0 for LMP7; S-LMP2, 5 0-GGA-
GAGCGGTGCCTTGCAGGGATGC-3 0 and AS-LMP2, 5 0-CATTG
CCCAAGATGACTCGATGGTC-3 0 for LMP2; S-MECL1, 5 0-CCA
AGATGCTGAAGCCAGCCCTGGA-30 and AS-MECL1, 5 0-ATGT
TCGGCTGGAACCGGTCTTCTA-3 0 for MECL1; S-G3PDH, 5 0-
TGAAGGTCGGAGTCAACGGATTTGGT-3 0 and AS-G3PDH,
5 0-CATGTGGGCCATGAGGTCCACCAC-3 0 for G3PDH. Hybrid-
ization was carried out at 42 C overnight for the former four genes
and at 68 C for 2 h for G3PDH.
Two transcripts of the human LMP7 gene (LMP7-E1 and -E2) [26]
were distinctively but simultaneously ampliﬁed by using multiplex
semi-quantitative RT-PCR. To this end, another primer S-LMP7-E1
(5 0-GGAAAGATTCAGAGACTGCGCCCT-3 0) was designed in
addition to aforementioned primers S-LMP7-E2 and AS-LMP7-E1/
E2 so that each transcript could be speciﬁcally ampliﬁed with the pair
of S-LMP7-E1/AS-LMP7-E1/E2 and of S-LMP7-E2/AS-LMP7-E1/
E2, respectively (Fig. 1B, top). Each reaction mixture contained 1 ll
of cDNA derived from either DLD-1 or DLD-1/TR/IRF-1-tag cells,
12.5 pmol of both S-LMP7-E1 and S-LMP7-E2 primers, and
25.0 pmol of AS-LMP7-E1/E2 primer in a 25-ll reaction containing
0.25 U of LA Taq polymerase (TaKaRa, Kyoto, Japan). The reaction
consisted of denaturation at 94 C for 30 s, annealing at 60 C for 30 s,
and extension at 72 C for 30 s. Eighteen cycles of reaction was per-
formed for both the multiplex PCR for LMP7 and conventional
PCR for G3PDH, since the ampliﬁcation for each gene was in the lin-
ear curve under these conditions. For control experiments, plasmids
pGEM-LMP7-E1 and -E2 were created by inserting the PCR-ampli-
ﬁed fragment with primer set of S-LMP7-E1 and AS-LMP7-E1/E2
or S-LMP7-E2 and AS-LMP7-E1/E2 into a pGEM-T Easy vector
(Promega, Madison, WI, USA), respectively. Equal amount of these
two plasmids were mixed and the PCR ampliﬁcation was performed
using 15 or 150 pg (7.5 or 75 pg for each plasmid) of the mixed
DNA as a template.
For murine studies, the quantities of mRNA for IRF-1, LMP7,
LMP2, MECL1, monokine induced by interferon-c (MIG) and b-actin
were determined by semi-quantitative RT-PCR. The primers and the
cycle numbers for the ampliﬁcation of each gene were as follows:
S-IRF-1, 5 0-ATGCCAATCACTCGAATGCG-3 0 and AS-IRF-1, 5 0-
TGGTGCACAAGGAATGGCCT-30 for IRF-1 (18 cycles); S-LM
P7, 5 0-CTCCGTGTCTGCAGCATCC-3 0 and AS-LMP7, 5 0-TCCA
CTTTCACCCAACCGTC-3 0 for LMP7 (23 cycles); S-LMP2, 5 0-TC
CACACCGGGACAACC-30 and AS-LMP2, 5 0-CCAGCCAGCTAC-
TATGAGATGC-3 0 for LMP2 (20 cycles); S-MECL1, 5 0-CGTCT-GCCCTTTACTGC-3 0 and AS-MECL1, 5 0-CCACTTCATTCCACC-
TCC-3 0 forMECL1 (21 cycles); S-MIG, 5 0-TGAAGTCCGCTGTTCT-
TTTCCT-3 0 and AS-MIG, 5 0-TTATGTAGTCTTCCTTGAACGA-
CG-3 0 for MIG (27 cycles); S-b-actin, 5 0-CCTAAGGCCAACCGT-
GAAAAG-3 0 and AS-b-actin, 5 0-TCTTCATGGTGCTAGGAGC-
CA-3 0 for b-actin (20 cycles). PCR products were separated on 1.8%
agarose gels, stained by ethidium bromide, and visualized by using a
Lumi-Imager F1 system (Roche, Mannheim, Germany).
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Cells were harvested, washed twice in ice cold PBS and lysed in a
buﬀer (50 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EDTA, 0.5% Triton
X-100, and complete protease inhibitor mix) for 15 min on ice. After
centrifugation for 10 min, the supernatants were used as whole cell ex-
tracts. Eighty micrograms of DLD-1 extracts or 160 lg of HeLa ex-
tracts was analyzed by using anti-LMP7 (Aﬃniti, Mamhead, UK),
anti-IRF-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
anti-b-actin (Sigma, Saint Louis, MO, USA) antibodies as described
elsewhere [24]. Proteins were visualized with an ECL system according
to the manufacturers instructions.
2.6. ChIP assays
Chromatin immunoprecipitation (ChIP) assays were performed as
described previously [24]. Brieﬂy, after ﬁxing DLD-1 cells with formal-
dehyde, soluble chromatin was extracted by sonicating the nuclei pellet
obtained by cellular lysis. The sheared chromatin of 500 bp was sub-
jected to immunoprecipitation with anti-IRF-1 antibody or control
IgG, and the co-immunoprecipitated DNA fragments were recovered
by reversing cross-linking. Puriﬁed DNA was analyzed by quantitative
PCR on a LightCycler system (Roche) by using six pairs of primers,
each of which could amplify 400 bp of the genomic DNA located
in the vicinity of the 5 0 part of the human LMP7 gene, to investigate
the region extending 2.5 kb in total (Fig. 3A, top). The following
primers were used: S-1, 5 0-GCTCCAGAATGAAAGCCTTCTCAG-
3 0, AS-1, 5 0-GCCGGAAACATAAGAAACCACAGT-3 0 for 957/
553 region; S-2, 5 0-CGGCACACCAAACGGCCCACTGCC-3 0,
AS-2, 5 0-TACTAGGCAATCCCGCCTACTGTT-3 0 for 556/148
region; S-3, 5 0-AAATATCTCCCATTCAGGGAGGCC-3 0, AS-3, 5 0-
CAACCAGAAGACTAGAAGTCAGCC-3 0 for 148/+290 region;
S-4, 5 0-AAGCTGCGCCTTTAGATGACACGA-30, AS-4, 5 0-ATA-
GAGAAACTGTAGTGTCCTGGG-3 0 for +291/+747 region; S-5,
5 0-TATGCGATCTCCAGAGCTCGCTTT-3 0, AS-5, 5 0-TCATAGGT-
TTCCCAAGACACCACA-3 0 for +745/+1118 region; S-6, 5 0-ATGAA-
ATTTGCCTGCTGGCCTCCT-3 0, AS-6, 5 0-GGAAGAATTCTGT-
GGGCTGATAAG-3 0 for +1115/+1560 region. The nucleotide
number was assigned relative to the transcription start site of the
LMP7-E1 transcript [26]. By using software provided by the manufac-
turer, the amount of DNA fragment in each sample was calculated rel-
ative to the standard curve obtained by the three diﬀerent dilutions of
input DNAs (10%, 1% and 0.1%). Three independent chromatin prep-
arations were made, and the average value obtained for each sample
was indicated as a percentage of total input DNA.
2.7. Reporter plasmid construction, transient transfection and reporter
assays
The LMP7-wild-type (wt)-Luc construct was made by inserting the
PCR-ampliﬁed genomic DNA fragment corresponding to the nucleo-
tide from 100 to +1601 of the human LMP7 gene into a pGL3-Basic
plasmid (Promega). The LMP7-mutant (mt)-Luc containing a 4-bp
mutationwithin the IRF-E at +581/+592was constructed by PCR-med-
iated mutagenesis. Wild-type sequences and the introduced mutations
within the IRF-E were given with top strand sequences as follows: wt,
+581GCTTTCGCTTTC+592; mt, +581GCCCTCGCCCTC+592
(underlined residues indicate introduced mutations). Either 5 lg of a
pGL3-basic, LMP7-wt-Luc or LMP7-mt-Luc plasmid along with
0.03 lg of a Renilla luciferase reporter plasmid pRL-TK-Luc (Prome-
ga), and either 0.1 lg of an expression vector pcDNA3-IRF-1 [24] or
a pcDNA3 (Invitrogen) were transiently transfected into HeLa cells
by using TransIT-LT1 transfection reagent (Mirus, Madison, WI,
USA). After transfection, cells were cultured in the presence or absence
of IFN-c (50 ng/ml) for 24 h. The determination of luciferase activities
and the data normalization were performed as described previously [24].
2.8. siRNA experiments
DLD-1 and HeLa cells were transfected with either small interfering
RNA (siRNA) oligonucleotides speciﬁc for human IRF-1 or control
oligonucleotides with nonsense sequence for 12 h as described previ-
ously [24]. After the removal of the siRNA-containing medium, cells
were cultured for an additional 12 h under the usual conditions, and
then the medium was exchanged with either medium alone or that con-
taining 50 ng/ml of human IFN-c. Cells were collected after 24 h of the
medium exchange, and the whole cell extracts were isolated and sub-
jected to Western blot analysis for IRF-1, LMP7, and b-actin.3. Results
3.1. Both IFN-c and IRF-1 upregulate mRNA expression of the
immunosubunits including LMP7
To examine the mechanism of inducible expression of LMP7
by IFN-c, we initially analyzed human colonic epithelium-
derived DLD-1 cells in which IFN-c could elicit several cellu-
lar responses such as production of cytokines [24,27]. When
expressions of LMP7, LMP2 and MECL1 were tested by
Northern blotting, mRNA of all these components of the
immunoproteasome was induced by IFN-c (Fig. 1A, left).
Since the kinetics of mRNA expression in response to IFN-c
was similar among these genes, it appeared likely that the tran-
scription of each gene is analogously regulated by IFN-c-
dependent signaling events. Previous studies demonstrated
that both LMP2 and MECL1 are transcriptionally regulated
by IRF-1 [18–21]. We, therefore, hypothesized that IRF-
1-mediated transcription might be also involved in IFN-c-
dependent LMP7 expression. To test this, we utilized a subline
DLD-1/TR/IRF-1 cells where the expression of IRF-1 was
conditionally regulated by use of the TET-on system [24]. As
shown in Fig. 1A (right), expression of IRF-1 mRNA was eﬃ-
ciently induced and reached a maximum level within 3 h of the
DOX addition in these cells, whereas no induction was ob-
served in control DLD-1/TR cells. Of note, this transcript of
IRF-1, originating from an artiﬁcially integrated gene, was dif-
ferent in size (1.6 kb; shown with \\) from that derived from
the endogenous one that could be induced by IFN-c (2.4 kb;
shown with \) (Fig. 1A, left). Hybridization with a probe for
either LMP2 or MECL1 showed a marked induction of these
mRNAs, conﬁrming the pivotal role of IRF-1 in the transcrip-
tion of both genes [18–21]. Intriguingly, following the expres-
sion of IRF-1, a signiﬁcant increase of the LMP7 mRNA
was also observed. In addition, this increase, seen from 3 to
12 h after stimulation with DOX, quite paralleled that of
LMP2 and MECL1 mRNAs. These results suggested that
the upregulation of LMP7 by IFN-c might be mediated by a
direct mechanism involving the IRF-1-mediated transcription.3.2. Both IFN-c and IRF-1 predominantly induce expression of
LMP7-E2 between two species of the human LMP7 mRNA
The human LMP7 gene codes for two alternative forms of
mRNAs, LMP7-E1 and LMP7-E2, that diﬀer in their 5 0 re-
gions encoding amino-terminal prosequences (Fig. 1B, top)
[26]. It was, however, demonstrated that only LMP7-E2 gives
rise to a functional protein that can be assembled into the pro-
teasome, possibly reﬂecting the crucial role of the amino-termi-
nal region in the following protein processing [28]. The probe
used in our Northern blotting, derived from the LMP7-E2
cDNA, broadly encompassed the common sequence for both
transcripts and, therefore, the observed bands should represent
the expression levels of both mRNA species. However, it was
also reported that the sizes of the two transcripts were indistin-
guishable in Northern blot analysis [26]. Thus, we next exam-
ined the content of these two mRNAs by using multiplex
RT-PCR allowing one-tube ampliﬁcation of cDNAs derived
from both transcripts. As shown in Fig. 1B (bottom), ampliﬁ-
cation with a sense primer speciﬁc for LMP7-E2 (S-E2) along
with an antisense primer common for both LMP7-E1 and -E2
(AS-E1/E2) yielded the product of the expected size (828 bp)
from the mRNA of unstimulated DLD-1 cells. By contrast,
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LMP7-E1, together with the AS-E1/E2 primer (956 bp) was
undetectable (Fig. 1B, bottom). Inability of the primer pair
S-E1/AS-E1/E2 to amplify the corresponding DNA fragment
was excluded, because both LMP7-E1 and -E2 fragments were
eﬃciently as well as simultaneously ampliﬁed when the mixture
of equal amount of two plasmids encoding LMP7-E1 and -E2,
respectively, was used as templates (Fig. 1B, bottom). Impor-
tantly, both IFN-c-treated parental DLD-1 and DOX-treated
DLD-1/TR-IRF-1-tag cells exhibited signiﬁcant induction of
the LMP7-E2 expression, whereas the change of the levels of
LMP7-E1 was not observed. These data indicated that
LMP7 mRNA, induced by either IFN-c or forced expression
of IRF-1 in DLD-1 cells, mainly consists of the transcript
LMP7-E2.
3.3. IRF-1-dependent transcription of the LMP7 gene leads to
expression of the processed form of LMP7 protein
It was shown that, by using HeLa cells, the LMP7-E2 tran-
script gives rise to a precursor protein of 28.5 kDa which is
subsequently processed into an end product of 23 kDa [26].
When the whole cell extracts from DLD-1 cells before and
after IFN-c treatment (24 h) were examined, the protein prod-
uct of approximately 23 kDa became visible upon IFN-c treat-
ment (Fig. 2). The size of this product corresponded to that of
a band observed in extracts from IFN-c-treated HeLa cells,
indicating that not only suﬃcient translation but also the fol-
lowing protein processing of LMP7 could be operational in
DLD-1 cells (Fig. 2). Interestingly, the conditional expression
of IRF-1 in DLD-1/TR/IRF-1-tag cells also resulted in the
induction of the 23-kDa protein, clearly showing that the acti-
vation of IRF-1 alone could be enough for the generation of
the processed form of LMP7 (Fig. 2).
3.4. IFN-c induces the binding of IRF-1 to the region +291/+747
of the human LMP7 gene
The putative binding sites for several transcription factors
were noted on a limited region approximately 800 bp upstream
of the exon 1 of the human LMP7 gene [26]. However, the
functional relevance of the transcriptional regulation to any
speciﬁc sequences within or in the proximity of this region
has remained undetermined. Therefore, we next tested whether
IRF-1 directly interacts with the 5 0 ﬂanking or intragenic re-
gion of the LMP7 gene by using ChIP assays with chromatin
extracts of DLD-1 cells [24]. We designed six pairs of PCRFig. 2. IRF-1 induces expression of the processed form of LMP7
protein. Parental DLD-1 (DLD-1) and HeLa cells, or DLD-1/TR/
IRF-1-tag (DLD-1/TR/IRF-1) cells were stimulated with IFN-c
(50 ng/ml) or DOX (100 ng/ml), respectively, and were collected before
and after 24 h of stimulation. Eighty micrograms of DLD-1 and DLD-
1/TR/IRF-1 cell extracts or 160 lg of HeLa cell extracts were subjected
to Western blot analysis. Immunoblot was initially performed with an
anti-LMP7 antibody and then followed by reprobing with an anti-b-
actin antibody.primers to amplify DNA fragments of 400 bp each, attempt-
ing to analyze the genomic region of approximately 2.5 kb in
total that extends both upstream and downstream of the tran-
scription start site of the LMP7-E1 (+1) (Fig. 3A, top). In the
absence of IFN-c, the speciﬁc binding of IRF-1 to this region
appeared to be scarce, because anti-IRF-1 antibody precipi-
tated only small amount of any fragment throughout the re-
gion (Fig. 3A, middle). By contrast, when cells were
stimulated with IFN-c, a signiﬁcant induction of the promoter
occupancy by IRF-1 was observed particularly within the re-
gion +291 to +747 (Fig. 3A, middle). These results suggested
that, upon stimulation with IFN-c, IRF-1 interacts with cer-
tain binding sites within the sequence from +291 to +747
and activates the LMP7 gene transcription. Indeed, a search
for potential binding sequences for the IRF family protein in
the entire region of 2.5 kb revealed a single sequence
GCTTTCGCTTTC at +581/+592, which completely matches
IRF-E consensus sequence, within the region from +291 to
+747. We also found four other potential sequences that
incompletely match the consensus IRF-E within this region;
one having two nucleotide mismatches and a nucleotide dele-
tion at +1417/+1427, and the others having three nucleotide
mismatches at 700/689, +411/+422 and +513/+524. How-
ever, from our ChIP data, we concluded that these sites do
not serve as critical binding sites for IRF-1 in response to
IFN-c stimulation.3.5. Both IFN-c and IRF-1 enhance the transcriptional activity
of the LMP7 gene via the IRF-E at +581/+592
To ascertain the functional involvement of the IRF-E at
+581/+592 in the LMP7 gene transcription, we constructed a
reporter plasmid carrying the region 100 to +1601 (LMP7-
wt-Luc). When HeLa cells were transiently transfected with
the plasmid and assayed, the reporter activity was signiﬁcantly
induced in response to IFN-c (Fig. 3B). When a mutated ver-
sion of the reporter gene (LMP7-mt-Luc), defective in binding
to IRF proteins due to a 4-bp mutation in the IRF-E, was ana-
lyzed in parallel, the IFN-c-dependent induction of reporter
activity was signiﬁcantly lower than that of the wild-type
LMP7-Luc (Fig. 3B). Interestingly, when assessed by cotrans-
fecting an expression vector encoding IRF-1, the forced
expression of IRF-1 resulted in a signiﬁcant enhancement of
the transcriptional activity of the LMP7-wt-Luc, while it had
little eﬀect on that of the LMP7-mt-Luc. Similar results were
obtained when the same series of experiments were carried
out by using DLD-1 cells, although the luciferase activities
were extremely lower than those in HeLa cells, probably
reﬂecting the low eﬃciency of transfection (data not shown).
Taken together, it was indicated that the IRF-E at +581/
+592 and its interaction with IRF-1 are functionally important
for inducible expression of the human LMP7 gene by IFN-c.3.6. Silencing IRF-1 results in marked reduction of the
IFN-c-dependent LMP7 protein expression
To address the involvement of IRF-1 in LMP7 expression
more directly, we next performed transient transfection exper-
iments of an IRF-1-speciﬁc siRNA oligonucleotide into DLD-
1 and HeLa cells and assessed its inﬂuences on LMP7 expres-
sion (Fig. 4). In our experimental system, the expression of
IRF-1 protein was suppressed by its speciﬁc siRNA to 20%
of the control in DLD-1 and to undetectable level in HeLa
Fig. 4. Silencing IRF-1 expression by its speciﬁc siRNA results in
marked reduction of LMP7 protein expression. Parental DLD-1 and
HeLa cells were transfected with either siRNA oligonucleotides
targeting IRF-1 (+) or control siRNA (). After transfection, cells
were cultured under the usual conditions for an additional 12 h and
then cultured in the presence (+) or absence () of IFN-c (50 ng/ml).
Cells were lysed after 24 h, and 80 lg of DLD-1 extracts or 160 lg of
HeLa extracts were subjected to Western blot analysis. Immunoblot
was performed with an anti-LMP7 antibody and sequentially followed
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4). Again, the diﬀerence in the potency of the siRNA treatment
was assumed to be due to that in the transfection eﬃciency be-
tween these cell types. As expected, reprobing the same blots
with anti-LMP7 antibodies revealed that the expression of
LMP7 upon IFN-c treatment was decreased below the detec-
tion levels in both cell types (Fig. 4). These data clearly indi-
cated that IRF-1 plays a major role in linking the IFN-c
action to the resultant expression of LMP7 protein.
3.7. IRF-1 functions as a critical mediator for IFN-c-dependent
expression of LMP7, LMP2 and MECL1 in vivo
The 5 0 part of the human and murine LMP7 genes shows the
approximately 290 bp region containing the IRF-E to be highly
conserved. Based on this notion, we assessed the role of IRF-1
in LMP7 expression in vivo by using IRF-1/ or wild-type
by reprobing with an anti-IRF-1 and an anti-b-actin antibody.
A
B
Fig. 5. IRF-1 functions as a critical mediator for IFN-c-dependent
expression of LMP7, LMP2 and MECL1 in vivo. IRF-1/ and wild-
type (IRF-1+/+) mice were injected i.p. with either murine IFN-c
(1 · 105 U/mouse) or vehicle alone (n = 2 per group). After 6 h of
injection, total RNAs from colon and liver tissues were isolated and
analyzed by semi-quantitative RT-PCR for LMP7, LMP2, MECL1,
IRF-1, MIG and b-actin. PCR products were electrophoresed and
visualized by ethidium bromide staining. Each lane represents a sample
from an individual mouse.control mice (Fig. 5). After intraperitoneal injection of mice
with murine IFN-c or sterile vehicle alone, total RNAs ex-
tracted from the colon and liver were subjected to semi-quanti-Fig. 3. IRF-1 binds to the region +291/+747, and the IRF-E at +581/
+592 within this region functions as a critical enhancer element in
human LMP7 gene transcription. (A) The genomic regions analyzed
by the ChIP assays were schematically shown with the 5 0 part of the
human LMP7 gene (top). Six pairs of the primers and each PCR-
ampliﬁed region were indicated with numbers through 1 to 6.
Nucleotide numbers were given as shown in Fig. 1B. The location of
a consensus sequence for IRF-E is also indicated (top). DLD-1 cells
were treated with IFN-c (50 ng/ml) or left untreated for 6 h and
processed for ChIP assays by using anti-IRF-1 antibody (middle) or
control IgG (bottom). Precipitated DNA was analyzed by quantitative
PCR to amplify each of six regions shown in the top panel. The
amount of immunoprecipitated fragment relative to that present in
total input chromatin (% of total input) was calculated as described in
Section 2. Data are shown as the means ± S.D. of three independent
chromatin immunoprecipitations. (B) Either 5 lg of a pGL3-basic
(control), LMP7-wt-Luc or LMP7-mt-Luc was transiently transfected
into HeLa cells along with 0.03 lg of a Renilla luciferase reporter pRL-
TK-Luc. One hundred nanograms of an expression vector pcDNA3-
IRF-1 was also cotransfected and the total amounts of DNA were
adjusted by adding the same amount of an empty expression vector.
Cells were cultured in the presence or absence of IFN-c (50 ng/ml) for
24 h, and the cellular lysates were assayed for reporter activities.
Results are the means ± S.D. of three independent experiments.
b
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with IFN-c, the levels of IRF-1 expression were signiﬁcantly
higher than those of the mice treated with the vehicle alone
(Fig. 5). Furthermore, expressions of three immunosubunits
of the proteasome, LMP7, LMP2 and MECL1, and also of
MIG, known as an inducible gene by IFN-c, were signiﬁcantly
increased in IFN-c-treated wild-type mice in both tissues (Fig.
5). In striking contrast, in IRF-1/ mice, virtually no induc-
tion of LMP7 and MECL1, or only a little induction of
LMP2 was detected in response to IFN-c (Fig. 5). We could
verify the eﬀects of IFN-c in IRF-1/ mice, because the
upregulation of MIG in response to IFN-c in IRF-1/ mice
was comparable to that in wild-type mice, reﬂecting the depen-
dence of its transcription not on IRF-1 but on other signaling
pathways downstream of the IFN-c action [29,30]. In addition,
it seemed reasonable that the expression of LMP2 was to some
extent upregulated by IFN-c in IRF-1/ mice, because its
expression was mediated by both IRF-1-dependent and -inde-
pendent mechanisms, the latter of which involves activation
of signal transducer and activator of transcription (STAT) pro-
teins [19,20]. Taken together, these data demonstrated that
IRF-1 serves as a critical regulator for IFN-c-mediated
LMP7 expression in parallel with its role in the induction of
LMP2 and MECL1 by IFN-c in vivo.4. Discussion
In this study, we provide the evidence that IRF-1 plays a
central role in the transcriptional regulation of the LMP7 gene
by taking several experimental approaches. It was demon-
strated that, by using siRNA-mediated gene silencing experi-
ments, IRF-1 mediates IFN-c-dependent LMP7 expression
in both DLD-1 and HeLa cells that are derived from diﬀerent
tissues of human origin. Additionally, we showed essential
roles of IRF-1 in IFN-c-dependent LMP7 gene expression
by analyzing two diﬀerent murine tissues. Together with the
fact that the genomic region surrounding the IRF-E of the hu-
man LMP7 gene is highly conserved with that of murine one, it
was strongly suggested that the mechanism of LMP7 gene
transcription by IRF-1 might be broadly conserved beyond
the cell types and the species.
Our study also demonstrated that not only mRNA but also
the processed protein product of LMP7 was eﬃciently induced
by the overexpression of IRF-1, which was irrespective of the
IFN-c action. This suggests that various signaling pathways or
the target molecules that are activated by IFN-c, other than
IRF-1, have little, if any, eﬀect on the following protein pro-
cessing of LMP7. It was previously indicated that the pro-
cessed form of the LMP7 protein could be readily generated
only if an expression plasmid for the LMP7-E2 was transfected
into HeLa cells [26,28]. These collective ﬁndings emphasize
that the cleavage of the precursor protein at its N-terminal site
is regulated by a certain yet unidentiﬁed mechanism preexist-
ing in most cell types, and that the most critical step for the
expression of functionally matured LMP7 protein may be its
transcriptional regulation by IRF-1.
Early studies analyzing the eﬀect of solely overexpressed
LMP7 in several cell lines yielded somewhat discordant results
with respect to the change of the cleavage speciﬁcity of the 20S
proteasome [11,31,32]. However, it has been becoming obvious
that the entire function of LMP7 on antigen processing maynot be simply accounted for by its own catalytic activity. For
example, recent studies have shown that the assembly of the
immunoproteasome consists of complex processes that require
interdependent incorporation of the three IFN-c-inducible
subunits, and that LMP7 contributes to the maturation of
an intermediate form of the immunoproteasome that contains
LMP2 and MECL1 [17]. Indeed, such cooperative mechanism
was conﬁrmed by the observation that simultaneous expres-
sion of all these three immunosubunits, even at relatively low
levels, could process certain epitopes with increased eﬃciency
[33,34]. In addition, the ﬁnding that even a catalytically inac-
tive mutant of LMP7 could facilitate a certain epitope genera-
tion when expressed in combination with LMP2 and MECL1
[15], via its eﬀect on induction of structural changes of the
immunoproteasomes, further support the notion that the con-
certed presence of the immunosubunits would be essential for
maximizing the function of the immunoproteasome. Impor-
tantly, recent data have demonstrated that not only IFN-c
but also other factors such as tumor necrosis factor-a (TNF-
a) could induce coordinated expression of the three immun-
osubunits in certain cell types [35]. Together with the notion
that IRF-1 could be upregulated by a variety of cytokines such
as TNF-a [36] or viral infection [37], we believe the present
data that the expression of LMP7 is regulated by IRF-1 in tune
with the other two immunosubunits LMP2 and MECL1 would
be of signiﬁcant importance, because this brings forward the
central role of IRF-1 in the reorganization of the proteao-
somes into immunoproteasomes, serving as a master switch
that enables the proper class I antigen processing and the fol-
lowing immune responses in a variety of situations.
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